Fisher & Paykel Healthcare Corporation Limited today announced its results for the full year ended 31 March 2021. Operating revenue was $1.97 billion, up 56% or 61% in constant currency. Net profit after tax was $524 million, up 82% over the previous financial year, or 94% in constant currency.
Managing Director and CEO Lewis Gradon said, “It has been an extraordinary year and we want to thank healthcare professionals for giving their all to care for patients, often under the most difficult conditions. We also want to acknowledge the people of Fisher & Paykel Healthcare for their commitment to delivering for our customers, and the partners and families of our employees for the invaluable contribution they have made.
“The unprecedented result was driven by our Hospital product group, which includes Optiflow™ and Airvo™ systems used to deliver nasal high flow therapy. Sales of our Hospital hardware and consumables have continued to track COVID-19 hospitalisation surges in countries around the world,” said Gradon.
Revenue for the Hospital product group was $1.50 billion, an increase of 87% over the previous financial year, or 94% in constant currency. Hospital products made up 76% of the company’s operating revenue.
“Although COVID-19 restrictions impacted sleep clinics and reduced OSA diagnosis rates, revenue for the Homecare product group was $466 million, an increase of 2% over the previous year, or 4% in constant currency.
“Gross margin decreased by 295 basis points for the year to 63% or a 165 basis points decline in constant currency. This includes increased freight costs and high airfreight utilisation, which adversely impacted constant currency gross margin by approximately 230 basis points. Freight and additional COVID-19 related costs were offset by overhead leverage due to volume increases outpacing cost growth during the year.
“To recognise the incredible contributions of our people, the Board has approved a profit-sharing bonus totalling $29 million for the 2021 financial year to be paid to everyone who has worked with us for a qualifying period. The company has also committed $20 million to establish the Fisher & Paykel Healthcare Foundation during the 2021 financial year. The Foundation’s charitable purposes include supporting and funding health research and programmes that improve access to healthcare, supporting environmental protection initiatives and promoting awareness of opportunities in science, technology, engineering and mathematics. The value of our total donations for the year, including product donations, was $26 million,” said Gradon.
The company’s directors have approved a final dividend of 22.0 cents per share, an increase of 42% on the final dividend last year. This brings the total dividend for the year to 38.0 cents per share, an increase of 38%. The final dividend, carrying full New Zealand imputation credit, will be paid on 7 July 2021 with a record date of 25 June 2021.
No guidance provided for the 2022 financial year
With the ongoing uncertainties of vaccinations, lockdowns, COVID-19 variants, localised waves and return to stable hospitalisation rates around the world, the company is not providing guidance for the 2022 financial year.
“We expect our Hospital and Homecare revenue for FY22 to be impacted by the number of COVID-19 related hospitalisations around the world,” said Gradon.
“There is a wide range of scenarios for both the timing of a ‘return to normal’ and to what extent a return to normal includes COVID-19 endemic hospitalisations. It is unclear at this stage when and if other respiratory hospitalisations and surgical procedures will return to pre-COVID levels, or whether countries will increase their investment in healthcare infrastructure.”
Given the wide range of scenarios and uncertainties, the company makes the following observations
in relation to the 2022 financial year:
Overview of key results for the 2021 financial year
About Fisher & Paykel Healthcare
Fisher & Paykel Fisher Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in more than 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.
Investor Relations Manager
+64 (0) 27 807 8073
GM - Corporate Communications
+64 (0) 21 713 911
Attached to this news release are the following additional documents:
Full Year Results Conference Call
Fisher & Paykel Healthcare will host a conference call today to discuss the results for the 2021 financial year. The conference call is scheduled to begin at 10:00am NZST, 8:00am AEST Thursday 27 May (5:00pm USEDT, Wednesday 26 May) and will be webcast simultaneously over the Internet.
To listen to the webcast, access the company’s website at www.fphcare.com/investor. An online archive of the event will be available approximately two hours after the webcast and will remain on the site for two weeks.
To attend the conference call, participants should dial in to one of the numbers below at least five minutes prior to the scheduled call time and identify yourself to the operator. When prompted, please quote the conference code of: 483205.
New Zealand: +64 9 913 3624
Australia: +61 2 9193 3719
Hong Kong: +852 3008 1533
International: +64 9 913 3624
United Kingdom: +44 330 336 9104
US/Canada: +1 929 477 0338
2021 Investor Series
Fisher & Paykel Healthcare will also hold a virtual Investor Series over three days between 1 June and 3 June 2021 (NZST). The Investor Series will provide participants with the opportunity to hear from management based in New Zealand and the United States on the company’s technology and therapies and gain further insights into the company’s strategy for long-term sustainable profitable growth. The series will be presented via webcast through three one-hour presentations over three days including Q&A sessions with management. To find out further information and register for the event, please visit www.fphcare.com/investor-series/
Record full year result for Fisher & Paykel Healthcare: net profit up 82%
Find clinical evidence and practice guidelines for delivering nasal high flow (aka HFNC) therapy.
Featuring under nose NIV masks (F&P Visairo) and full face NIV masks - (F&P Nivairo), with vented and non-vented options to suit your hospital NIV mask needs.
Providing Optimal Humidity for intubated patients
Establish effective spontaneous breathing or assist ventilation of the lungs
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that provides a continuous distending pressure
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment